Search Technologies

The National Institute on Drug Abuse’s Medicinal Chemistry Section seeks partners interested in collaborative research to co-develop analogues of modafinil for the treatment of drug abuse and sleep and attention disorders.

The National Cancer Institute seeks parties interested licensing or collaborative research to co-develop thalidomide analogs to treat cancer and inflammatory diseases.

Researchers at the National Cancer Institute have discovered small molecule inhibitors of Chk2 for the treatment of cancer.

Scientists at NIH have identified 7 new agonist epitopes of the MUC-1 tumor associated antigen. Compared to their native epitope counterparts, peptides reflecting these agonist epitopes have been shown to enhance the generation of human tumor cells, which in turn have a greater ability to kill human tumor cells endogenously expressing the native MUC-1 epitope.

Investigators at the National Cancer Institute's Vaccine Branch have identified and enhanced immunogenicity of POTE epitopes to improve their efficacy in cancer vaccines.

The Eunice Kennedy Shriver National Institute of Child Health and Human Development seeks research co-development partners and/or licensees to further develop and commercialize PIKfyve phosphatidyl linositol kinase inhibitors for the treatment of pathogenic coronaviruses.

The National Cancer Institute seeks parties interested in licensing a new class of small molecules for the treatment of prostate cancer.

Researchers at NCI developed a rabbit monoclonal antibody that recognizes the marker for CD133 and is useful in pharmacodynamic testing to inform targeted anti-cancer chemotherapy development and clinical monitoring. CD133 is a cell surface glycoprotein used as a marker and expressed in stem cells such as hematopoietic stem cells, endothelial progenitor cells and neural stem cells. The NCI seeks collaborative co-development or licensing partners for this technology.

The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for small molecules that inhibit histone lysine demethylases (KDMs). These compounds may be effective therapeutics for Rhabdomyosarcoma (RMS) and other cancers.